Overview

  • Product name

    Satraplatin, platinum (IV) antitumor agent
  • Description

    Selective platinum (IV) antitumor agent
  • Alternative names

    • JM216
  • Biological description

    Selective platinum (IV) antitumor agent (IC50 = 2 μM). Lacks cross-resistance with cisplatin (Asc 1398). Active in vivo. Orally active.
  • Purity

    > 98%
  • CAS Number

    129580-63-8
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • McKeage MJ  et al. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother Pharmacol 36:451-8 (1995). Read more (PubMed: 7554035) »
  • Kelland LR  et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581-6 (1993). Read more (PubMed: 8388318) »
  • Selting KA  et al. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors. J Vet Intern Med 25:909-15 (0). Read more (PubMed: 21564292) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142679.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up